

DAFTAR PUSTAKA

1. Kumar V, Abbas A, Aster J, Turner J. Robbins & Cotran Pathologic Basis of Disease. 10 ed. Philadelphia: Elsevier; 2021. 1016–22.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* Mei 2021;71(3).
3. Globocan. Cancer Incident in Indonesia. *Int Agency Res Cancer.* 2020;858:1–2.
4. Riskesdas. Riset Kesehatan Dasar Provinsi Sumatera Barat Tahun 2018. *Lap Riskesdas Nas 2018.* 2019;112.
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* Januari 2022;72(1):7–33.
6. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Womens Heal.* 2019;11:287–99.
7. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. *CA Cancer J Clin.* 2019;69:280–304.
8. Harsono AB. Kanker ovarium : “The silent killer.” *Indones J Obstet Gynecol Sci.* 2020;3(1):1–6.
9. Aziz MF, Andrijono, Saifuddin AB, editor. *Onkologi Ginekologi: Buku Acuan Nasional.* 1 ed. Jakarta: PT Bina Pustaka Sarwono Prawihardjo; 2010. 469–526.
10. Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer. *Hematol Oncol Clin North Am.* 2018;32(6):943–64.
11. Berek JS, Hacker NF. *Gynecologic Oncology.* 7th ed. Philadelphia: Wolters Kluwer; 2020. 418–98.
12. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet.* 2019;393(10177):1240–53.
13. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: a comprehensive review. *Cancers (Basel).* 2020;12(3730):1–29.
14. Yuan Q, Song J, Yang W, Wang H, Huo Q, Yang J, et al. The effect of CA125 on metastasis of ovarian cancer: old marker new function. *Oncotarget.* 2017;8(30):50015–22.
15. Sánchez Vega JF, Murillo Bacilio M del R, Vintimilla Condoy AS, Palta González AM, Crespo Astudillo JA, Mora-Bravo FG. Predictive equation of

- metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker. *BMC Cancer*. 2018;18(1):1–5.
16. Gubbels JAA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. *Mol Cancer*. 2010;9:1–14.
 17. Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. *Am J Pathol*. 2021;191(1):26–39.
 18. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. *Best Pract Res Clin Obstet Gynaecol*. 2016;41:1–12.
 19. Gaona-Luviano P, Adriana L, Medina-Gaona, Magaña-Pérez K. Epidemiology of ovarian cancer. *Chinese Clin Oncol*. 2020;9(4):1–7.
 20. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. *Int J Mol Sci*. 2019;20(4):1–33.
 21. Disaia PJ, Creasman WT, Mannel RS, DS M, D M. *Clinical Gynecology Oncology*. 9 ed. Philadelphia: Elsevier; 2018. 236–52.
 22. Singla A. Epidemiology and risk factors for ovarian cancer. *Prev Oncol Gynecol*. 2019;223–31.
 23. Chen S, Li Y, Qian L, Deng S, Liu L, Xiao W, et al. A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer. *Front Oncol*. 2021;11(June):1–13.
 24. Rampersad AC, Wang Y, Smith ER, Xu X xi. Menopause and ovarian cancer risk : mechanisms and experimental support. *Am J Clin Exp Obs Gynecol*. 2015;2(1):14–23.
 25. Paulsen F, Waschke J. *Sobotta Atlas Anatomi Manusia*. 24 ed. Gunardi S, Isabella Liem, Kusumaningtyas S, editor. Jakarta: Elsevier Ltd; 2019. 291.
 26. Mescher, A L. *Jonqueira's Basic Histology*. McGraw-Hill Education. 2017. 449.
 27. Cunningham FG, Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL. *William Obstetric Text Book 25*. McGraw-Hill Education. 2018. 28–9.
 28. Kroeger PT, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer. *Curr Opin Obstet Gynecol*. 2017;29(1):26–34.
 29. Brown Y, Hua S, Tanwar PS. Extracellular matrix in high-grade serous ovarian cancer: Advances in understanding of carcinogenesis and cancer biology. *Matrix Biol*. 2023;118:16–46.
 30. Ricci F, Affatato R, Carrassa L, Damia G. Recent insights into mucinous ovarian carcinoma. *Int J Mol Sci*. 2018;19(6):1–4.
 31. Pierson WE, Peters PN, Chang MT, Chen L may, Quigley DA, Ashworth A, et al. An integrated molecular profile of endometrioid ovarian cancer.

- Gynecol Oncol. 2020;157(1):55–61.
32. Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary: a clinical and molecular perspective. *Int J Gynecol Cancer*. 2021;31(4):605–16.
 33. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Non-epithelial ovarian cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29:(iv)1–18.
 34. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *J Ovarian Res*. 2019;12(1):1–9.
 35. Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S, et al. Recent insight about HE4 role in ovarian cancer oncogenesis. *Int J Mol Sci*. 2023;24(13):1–7.
 36. Olsen M, Lof P, Stiekema A, van den Broek D, Wilthagen EA, Bossuyt PM, et al. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand*. 2021;100(10):1788–99.
 37. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *Int J Gynecol Obstet*. 2021;155(S1):61–85.
 38. Yousefi M, Dehghani S, Nosrati R, Ghanei M, Salmaninejad A, Rajaie S, et al. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. *Cell Oncol*. 2020;43(4).
 39. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. *J Natl Compr Cancer Netw*. 2021;19(2):191–226.
 40. Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker WM, et al. MUC16 as a novel target for cancer therapy. *Expert Opin Ther Targets*. 2018;22(8):675–86.
 41. Zhang R, Siu MKY, Ngan HYS, Chan KKL. Molecular biomarkers for the early detection of ovarian cancer. *Int J Mol Sci*. 2022;23(19):1–16.
 42. Giamougiannis, Panagiotis, Pierre L Martin-Hirsch FLM. The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. *Carcinogenesis*. 2021;42(3):327–43.
 43. Howe T, Sokolovsky N, Sayasneh A, Omar K, Tahmasebi F. Raised CA125 – what we actually know.... *Obstet Gynaecol*. 2021;23(1):21–7.
 44. Akinwunmi BO, Babic A, Vitonis AF, Cramer DW, Titus L, Tworoger SS, et al. Chronic medical conditions and CA125 levels among women without ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 2018;27(12):1483–90.

45. Núñez J, Bayés-Genís A, Revuelta-López E, ter Maaten JM, Miñana G, Barallat J, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. *Heart Fail.* 2020;8(5):386–97.
46. Bottoni P, Scatena R. The role of CA 125 as tumor marker: Biochemical and clinical aspects. *Adv Exp Med Biol.* 2015;867:229–44.
47. Hayati A, Tjahjadi H. Profil klinikopatologik metastasis kelenjar getah bening pada karsinoma ovarium di departemen patologi anatomik FKUI/RSCM 2016-2018. *Maj Patol Indones.* 2023;32(1):591–7.
48. KURNIADI A, HIDAYAT YM, SUARDI D, SUSANTO H, N.A.W G, PRAYITNO H. Peran serum IL-6 dan CA-125 prabedah sebagai prediktor resektabilitas tumor pada kanker ovarium tipe epitel. *Indones J Cancer.* 2018;11(4):151.
49. Dhitayoni I, Budiana I. Profil pasien kanker ovarium di rumah sakit umum pusat sanglah Denpasar – Bali periode Juli 2013 – Juni 2014. *E-Jurnal Med.* 2017;6(3):1–9.
50. Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, et al. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. *Gynecol Oncol.* 2018;150(3):460–5.
51. De Leo A, Santini D, Ceccarelli C, Santandrea G, Palicelli A, Acquaviva G, et al. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 world health organization classification of female genital tumors. *Diagnostics.* 2021;11(4):2–4.
52. Funston G, Mounce LTA, Price S, Rous B, Crosbie EJ, Hamilton W, et al. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: A retrospective cohort study using electronic health records. *Br J Gen Pract.* 2021;71(707):E465–72.
53. Zamani N, Mousavi AS, Akhavan S, Sheikhhasani S, Nikfar S, Feizabad E, et al. Uterine involvement in epithelial ovarian cancer and its risk factors. *J Ovarian Res.* 2021;14(171):1–7.
54. Ma X. The omentum, a niche for premetastatic ovarian cancer. *J Exp Med.* 2020;217(4):1.
55. Dai L, Song K, Di W. Adipocytes: active facilitators in epithelial ovarian cancer progression? *J Ovarian Res* 2020 131. 2020;13(1):1–13.
56. Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, et al. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. *Semin Cancer Biol.* 2022;86:207–23.
57. Qu Y, He Y, Li Z, Chen X, Liu Q, Zou S, et al. Constructing an ovarian cancer metastasis index by dissecting medical records. *Oncotarget.* 2017;8(60):102212–22.
58. Del Piccolo N, Shirure VS, Bi Y, Goedegebuure SP, Gholami S, Hughes

- CCW, et al. Tumor-on-chip modeling of organ-specific cancer and metastasis. *Adv Drug Deliv Rev.* 2021;175:1–21.
59. Aslan K, Onan MA, Yilmaz C, Bukan N, Erdem M. Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses. *J Gynecol Obstet Hum Reprod.* 2020;49(5):101713.
 60. Lee M, Chang MY, Yoo H, Lee KE, Chay DB, Cho H, et al. Clinical significance of CA125 level after the first cycle of chemotherapy on survival of patients with advanced ovarian cancer. *Yonsei Med J.* 2016;57(3):580–7.
 61. Wang X, Sun L, Li S, Guo J. Relationship between clinicopathological features of ovarian cancer with CA125, 199 and FIGO staging. *Int J Clin Exp Med.* 2020;13(11):8700–6.
 62. Tang Y, Hu HQ, Tang YL, Tang FX, Zheng XM, Deng LH, et al. Preoperative LMR and serum CA125 level as risk factors for advanced stage of ovarian cancer. *J Cancer.* 2021;12:5923–8.
 63. Huo Q, Xu C, Shao Y, Yu Q, Huang L, Liu Y, et al. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway. *Int J Biol Sci.* 2021;17(2):574–88.
 64. Thériault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. *Gynecol Oncol.* 2011;121(3):434–43.
 65. Giannakouros P, Comamala M, Matte I, Rancourt C, Piché A. MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β -catenin signaling. *Am J Cancer Res.* 2015;5(1):219–30.
 66. Wang X, Chen X, Li X, Wang X, Zhu Q, Wu X. MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: An original research. *BMC Cancer.* 2019;19(1):1–12.
 67. Wang F, Zhao X, Tan W, Liu W, Jin Y, Liu Q. Early identification of recurrence in ovarian cancer: a comparison between the ovarian cancer metastasis index and CA-125 levels. *PeerJ.* 2018;2018(11).